TMS-derived Short Afferent Inhibition Discriminates Cognitive Status in Older Adults Without Dementia

Overview

Journal Aging Brain

Publisher Elsevier

Specialty Geriatrics

Date 2024 Aug 12

PMID 39132326

Authors

Mark H Sundman

Jacob M Green

Andrew J Fuglevand

Ying-Hui Chou

Affiliations

Soon will be listed here.

Abstract

Aging is a complex and diverse biological process characterized by progressive molecular, cellular, and tissue damage, resulting in a loss of physiological integrity and heightened vulnerability to pathology. This biological diversity corresponds with highly variable cognitive trajectories, which are further confounded by genetic and environmental factors that influence the resilience of the aging brain. Given this complexity, there is a need for neurophysiological indicators that not only discern physiologic and pathologic aging but also closely align with cognitive trajectories. Transcranial Magnetic Stimulation (TMS) may have utility in this regard as a non-invasive brain stimulation tool that can characterize features of cortical excitability. Particularly, as a proxy for central cholinergic function, short-afferent inhibition (SAI) dysfunction is robustly associated with cognitive deficits in the latter stages of Alzheimer's Disease and Related Dementia (ADRD). In this study, we evaluated SAI in healthy young adults and older adults who, though absent clinical diagnoses, were algorithmically classified as cognitively normal (CN) or cognitively impaired (CI) according to the Jak/Bondi actuarial criteria. We report that SAI is preserved in the Old-CN cohort relative to the young adults, and SAI is significantly diminished in the Old-CI cohort relative to both young and CN older adults. Additionally, diminished SAI was significantly associated with impaired sustained attention and working memory. As a proxy measure for central cholinergic deficits, we discuss the potential value of SAI for discerning physiological and pathological aging.

References

Martorana A, Esposito Z, Di Lorenzo F, Giacobbe V, Sancesario G, Bucchi G . Cerebrospinal fluid levels of Aβ42 relationship with cholinergic cortical activity in Alzheimer's disease patients. J Neural Transm (Vienna). 2012; 119(7):771-8. DOI: 10.1007/s00702-012-0780-4. View

Grothe M, Heinsen H, Teipel S . Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer's disease. Neurobiol Aging. 2012; 34(4):1210-20. PMC: 4058576. DOI: 10.1016/j.neurobiolaging.2012.10.018. View

Garibotto V, Tettamanti M, Marcone A, Florea I, Panzacchi A, Moresco R . Cholinergic activity correlates with reserve proxies in Alzheimer's disease. Neurobiol Aging. 2013; 34(11):2694.e13-8. DOI: 10.1016/j.neurobiolaging.2013.05.020. View

Xia Y, Eeles E, Fripp J, Pinsker D, Thomas P, Latter M . Reduced cortical cholinergic innervation measured using [F]-FEOBV PET imaging correlates with cognitive decline in mild cognitive impairment. Neuroimage Clin. 2022; 34:102992. PMC: 8958543. DOI: 10.1016/j.nicl.2022.102992. View

Ballinger E, Ananth M, Talmage D, Role L . Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline. Neuron. 2016; 91(6):1199-1218. PMC: 5036520. DOI: 10.1016/j.neuron.2016.09.006. View

Sabri O, Kendziorra K, Wolf H, Gertz H, Brust P . Acetylcholine receptors in dementia and mild cognitive impairment. Eur J Nucl Med Mol Imaging. 2008; 35 Suppl 1:S30-45. DOI: 10.1007/s00259-007-0701-1. View

Andre C, Martineau-Dussault M, Daneault V, Blais H, Frenette S, Lorrain D . REM sleep is associated with the volume of the cholinergic basal forebrain in aMCI individuals. Alzheimers Res Ther. 2023; 15(1):151. PMC: 10485959. DOI: 10.1186/s13195-023-01265-y. View

Stern Y . Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol. 2012; 11(11):1006-12. PMC: 3507991. DOI: 10.1016/S1474-4422(12)70191-6. View

Quintana D, Williams D . Bayesian alternatives for common null-hypothesis significance tests in psychiatry: a non-technical guide using JASP. BMC Psychiatry. 2018; 18(1):178. PMC: 5991426. DOI: 10.1186/s12888-018-1761-4. View

10.

Kendziorra K, Wolf H, Meyer P, Barthel H, Hesse S, Becker G . Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. Eur J Nucl Med Mol Imaging. 2010; 38(3):515-25. DOI: 10.1007/s00259-010-1644-5. View

11.

Boyle P, Wilson R, Yu L, Barr A, Honer W, Schneider J . Much of late life cognitive decline is not due to common neurodegenerative pathologies. Ann Neurol. 2013; 74(3):478-89. PMC: 3845973. DOI: 10.1002/ana.23964. View

12.

Turco C, El-Sayes J, Locke M, Chen R, Baker S, Nelson A . Effects of lorazepam and baclofen on short- and long-latency afferent inhibition. J Physiol. 2018; 596(21):5267-5280. PMC: 6209752. DOI: 10.1113/JP276710. View

13.

Wolf D, Grothe M, Fischer F, Heinsen H, Kilimann I, Teipel S . Association of basal forebrain volumes and cognition in normal aging. Neuropsychologia. 2013; 53:54-63. DOI: 10.1016/j.neuropsychologia.2013.11.002. View

14.

Lai Y, Hsu F, Yeh S, Kuo Y, Lin H, Lin Y . Atrophy of the cholinergic regions advances from early to late mild cognitive impairment. Neuroradiology. 2024; 66(4):543-556. DOI: 10.1007/s00234-024-03290-6. View

15.

Lopez-Otin C, Blasco M, Partridge L, Serrano M, Kroemer G . The hallmarks of aging. Cell. 2013; 153(6):1194-217. PMC: 3836174. DOI: 10.1016/j.cell.2013.05.039. View

16.

Abdelnour C, Agosta F, Bozzali M, Fougere B, Iwata A, Nilforooshan R . Perspectives and challenges in patient stratification in Alzheimer's disease. Alzheimers Res Ther. 2022; 14(1):112. PMC: 9375274. DOI: 10.1186/s13195-022-01055-y. View

17.

Fernandez-Cabello S, Kronbichler M, Van Dijk K, Goodman J, Nathan Spreng R, Schmitz T . Basal forebrain volume reliably predicts the cortical spread of Alzheimer's degeneration. Brain. 2020; 143(3):993-1009. PMC: 7092749. DOI: 10.1093/brain/awaa012. View

18.

Schumacher J, Thomas A, Peraza L, Firbank M, Cromarty R, Hamilton C . EEG alpha reactivity and cholinergic system integrity in Lewy body dementia and Alzheimer's disease. Alzheimers Res Ther. 2020; 12(1):46. PMC: 7178985. DOI: 10.1186/s13195-020-00613-6. View

19.

Hampel H, Cummings J, Blennow K, Gao P, Jack Jr C, Vergallo A . Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat Rev Neurol. 2021; 17(9):580-589. DOI: 10.1038/s41582-021-00520-w. View

20.

Veitch D, Weiner M, Aisen P, Beckett L, Cairns N, Green R . Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement. 2018; 15(1):106-152. DOI: 10.1016/j.jalz.2018.08.005. View